| Literature DB >> 25448752 |
Meng Lv1, Zhuo Chen1, Gaoyun Hu2, Qianbin Li3.
Abstract
Diabetic nephropathy (DN) is one of the most common complications of diabetes with high mortality rates worldwide. The treatment of DN has posed a formidable challenge to the scientific community. Simple control of risk factors has been insufficient to cope with the progression of DN. During the process of anti-DN drug discovery, multiple pathogeneses such as oxidative stress, inflammation and fibrosis should all be considered. In this review, the pathogenesis of DN is summarized. The major context focuses on a few small molecules toward the pathogenesis available in animal models and clinical trials for the treatment of DN. The perspectives of novel anti-DN agents and the future directions for the prevention of DN are discussed.Entities:
Mesh：
Substances：
Year: 2014 PMID： 25448752 DOI： 10.1016/j.drudis.2014.10.007
Source DB: PubMed Journal: Drug Discov Today ISSN： 1359-6446 Impact factor: 7.851